Saltar al contenido
Merck
Todas las fotos(3)

Documentos clave

Ver Toda la documentación

A4669

Sigma-Aldrich

Acycloguanosine

≥99% (HPLC), powder

Sinónimos:

9-[(2-Hydroxyethoxy)methyl]guanine, Acyclovir

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(3)

About This Item

Fórmula empírica (notación de Hill):
C8H11N5O3
Número de CAS:
59277-89-3
Peso molecular:
225.20
Número CE:
261-685-1
Número MDL:
MFCD00057880
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
24278078
NACRES:
NA.77

Ensayo

≥99% (HPLC)

Formulario

powder

color

white

solubilidad

H2O: 0.7 mg/mL
1 M HCl: 50 mg/mL
DMSO: 7 mg/mL

ε (coeficiente de extinción)

11.8 at 256 nm at 1 mM

espectro de actividad antibiótica

viruses

Modo de acción

DNA synthesis | interferes

emisor

GlaxoSmithKline

cadena SMILES

NC1=Nc2c(ncn2COCCO)C(=O)N1

InChI

1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)

Clave InChI

MKUXAQIIEYXACX-UHFFFAOYSA-N

Información sobre el gen

human ... HV1S(3365) , NP(4860)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Acycloguanosine or acyclovir is a guanosine analog.

Aplicación

Acycloguanosine has been used as an inhibitor of herpes simplex virus type I:
  • to serve as a positive control to compare the antiviral activities of mushroom extracts in cytotoxic assays using Vero cells
  • in infection studies to test its effect on voltage-gated sodium channels (VGSC) using human dorsal root ganglion-derived neuronal (HD10.6) cells
  • to test its effect on the interferon-stimulated gene (ISG) expression induction (Mx1 and ISG15) in human foreskin fibroblast cells

Acciones bioquímicas o fisiológicas

Acycloguanosine is an antiviral agent and is converted to acycloguanosine triphosphate by herpes simplex virus thymidine kinase (HSV-TK). It competitively inhibits the viral DNA polymerase. It is less effective against cytomegalovirus and Epstein-Barr virus. Acycloguanosine has been used to study herpes simplex virus latency. It may act against human immunodeficiency virus 1 (HIV-1) as well.

Características y beneficios

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Equipo de protección personal

Eyeshields, Gloves, type N95 (US)

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
117F0756

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Antiviral nanodelivery systems: current trends in acyclovir administration
Haniza H, et al.
Journal of Nanomaterials (2016)
L Z Rubsam et al.
Cancer research, 58(17), 3873-3882 (1998-09-10)
Enzyme-prodrug therapy using ganciclovir and herpes simplex virus-thymidine kinase (HSV-TK) has demonstrated excellent antitumor activity in many different types of malignant cells. Previously, we noted that ganciclovir was substantially more cytotoxic than other HSV-TK substrates. Therefore, we embarked on a
Adalbert Krawczyk et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(17), 6760-6765 (2013-04-10)
Despite the availability of antiviral chemotherapy, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections remain a severe global health problem. Of particular concern is the growing incidence of drug resistance in immunocompromised patients, which stresses the urgency
Daniel S Owers et al.
The Cochrane database of systematic reviews, 2(2), CD005133-CD005133 (2013-03-02)
Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid organ transplant recipients. Pre-emptive treatment of patients with CMV viraemia using antiviral agents has been suggested as an alternative to routine prophylaxis to prevent CMV disease. This is
Sonia Burrel et al.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 58(1), 321-324 (2013-06-05)
Herpes simplex virus type 1 (HSV-1) is a leading cause of corneal blindness. Acyclovir (ACV) constitutes the standard treatment of HSV infections including herpetic keratitis (HK). HSV resistance to ACV is mainly described in immunocompromised patients. We describe two cases
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico